| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 56,590 | 46,740 | 38,030 | 0 | 0 |
| Sales Growth | +21.07% | +22.90% | unch | unch | unch |
| Net Income | -72,810 | -114,330 | -23,360 | 780 | -10 |
| Net Income Growth | +36.32% | -389.43% | -3,094.87% | +7,900.78% | unch |
Scilex Holding Co.
(SCLX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Scilex Holding Company is a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain. Scilex Holding Company, formerly known as Vickers Vantage Corp. I, is based in PALO ALTO, Calif.
Fiscal Year End Date: 12/31